SCHEMBL19765002

SCHEMBL19765002

Clc1c(Br)ccc2c1OCCO2

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.39
HTT P42858 3/20 0.39
MAPT P10636 1/20 0.39
BLM P54132 1/20 0.39
ITGB2 P05107 1/20 0.37
ICAM1 P05362 1/20 0.37
ITGAL P20701 1/20 0.37
HTR2A P28223 1/20 0.36
HTR2C P28335 1/20 0.36
HTR2B P41595 1/20 0.36
AOC3 Q16853 1/20 0.36
MAOB P27338 6/20 0.35
CRHBP P24387 2/20 0.33
CRHR2 Q13324 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
KDM4E B2RXH2 2/20 0.33
ALDH1A1 P00352 1/20 0.33
HPGD P15428 1/20 0.33
HSD17B10 Q99714 1/20 0.33
ADRB1 P08588 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30329793 0.77 LMNA (0.38) LMNAHTTMAPTBLMITGB2
SCHEMBL30949613 0.77 HTR2A (0.43) LMNAHTTMAPTBLMITGB2
SCHEMBL20741822 0.77 HTR2A (0.43) LMNAHTTMAPTBLMITGB2
SCHEMBL20729436 0.77 ALDH1A1 (0.39) LMNAHTTMAPTITGB2ICAM1
SCHEMBL2026290 0.77 LMNA (0.38) LMNAHTTMAPTBLMITGB2
SCHEMBL25166334 0.77 LMNA (0.38) LMNAHTTMAPTBLMITGB2
SCHEMBL7473749 0.77 ADRA2A (0.44) LMNAHTTMAPTBLMITGB2
SCHEMBL25844876 0.76 AOC3 (0.46) LMNAHTTMAPTBLMITGB2
SCHEMBL17397871 0.74 KDM4E (0.40) LMNAHTTMAPTBLMITGB2
SCHEMBL29185352 0.74 HTR2A (0.37) LMNAHTTMAPTBLMITGB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11793771-B2 Immunomodulator compounds CHEMOCENTRYX, INC. (US) 2023-10-24 US disclosed
US-11793771-B2 Immunomodulator compounds CHEMOCENTRYX, INC. (US) 2023-10-24 US disclosed
US-20180008554-A1 IMMUNOMODULATOR COMPOUNDS CHEMOCENTRYX, INC. 2018-01-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11793771-B2 Immunomodulator compounds IL2, IL2RA, C3AR1 LMNA 4728/4885HTT 4445/4885MAPT 4837/4885
US-20180008554-A1 IMMUNOMODULATOR COMPOUNDS IL2, IL2RA, C3AR1 LMNA 4704/4885HTT 4485/4885MAPT 4795/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.